Repare Therapeutics Stock Today
| RPTX Stock | USD 2.81 0.16 5.39% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Repare Therapeutics is trading at 2.81 as of the 24th of November 2024; that is 5.39 percent decrease since the beginning of the trading day. The stock's open price was 2.97. Repare Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Repare Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of December 2022 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of June 2020 | Category Healthcare | Classification Health Care |
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company was incorporated in 2016 and is headquartered in Montreal, Canada. The company has 42.51 M outstanding shares of which 749.74 K shares are at this time shorted by private and institutional investors with about 6.38 trading days to cover. More on Repare Therapeutics
Moving against Repare Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Repare Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Lloyd Segal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRepare Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Repare Therapeutics' financial leverage. It provides some insight into what part of Repare Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repare Therapeutics (RPTX) is traded on NASDAQ Exchange in USA. It is located in 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9 and employs 179 people. Repare Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 119.46 M. Repare Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 42.51 M outstanding shares of which 749.74 K shares are at this time shorted by private and institutional investors with about 6.38 trading days to cover.
Repare Therapeutics currently holds about 282.09 M in cash with (127.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Repare Therapeutics Probability Of Bankruptcy
Ownership AllocationRepare Therapeutics owns a total of 42.51 Million outstanding shares. The majority of Repare Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Repare Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Repare Therapeutics. Please pay attention to any change in the institutional holdings of Repare Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Repare Ownership Details
Repare Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nikko Asset Management Americas Inc | 2024-06-30 | 277.2 K | |
| Millennium Management Llc | 2024-06-30 | 249.5 K | |
| Sumitomo Mitsui Trust Group Inc | 2024-09-30 | 249.2 K | |
| Gsa Capital Partners Llp | 2024-09-30 | 240.5 K | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 173.4 K | |
| D. E. Shaw & Co Lp | 2024-06-30 | 149.6 K | |
| Squarepoint Ops Llc | 2024-06-30 | 143 K | |
| Blackrock Inc | 2024-06-30 | 141.8 K | |
| Citadel Advisors Llc | 2024-06-30 | 140.4 K | |
| Bvf Inc | 2024-09-30 | 10.3 M | |
| Blue Owl Capital Holdings Lp | 2024-06-30 | 3.4 M |
Repare Therapeutics Historical Income Statement
Repare Stock Against Markets
Repare Therapeutics Corporate Management
| Michael Zinda | Executive Officer | Profile | |
| Maria MD | Executive Officer | Profile | |
| Agnel Sfeir | CoFounder | Profile | |
| Cameron Black | Executive Discovery | Profile | |
| Kim Seth | Executive Officer | Profile | |
| Philip Herman | Ex Devel | Profile | |
| Daniel Belanger | Executive Resource | Profile |
Additional Tools for Repare Stock Analysis
When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.